Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis c infection

Iranian Journal of Kidney Diseases

Volumn 4, Issue 3, 2010, Pages 181-194

  Alavian, Seyed Moayed ^a   Tabatabaei, Seyed Vahid ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hemodialysis; Hepatitis C virus; Interferons; Treatment outcome

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; VIRUS RNA;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; CLINICAL TRIAL; DISEASE DURATION; DRUG RESPONSE; FEMALE; GENDER; GENOTYPE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; LIVER FIBROSIS; MALE; META ANALYSIS; MONOTHERAPY; REVIEW; SUSTAINED VIROLOGICAL RESPONSE; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RENAL DIALYSIS;

EID: 77955384548     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Fallah Huseini H, Alavian SM, Toliat T, et al. The efficacy of herbal medicine Khar Maryam (Silybum marianum (L.) Gaertn.) on liver cirrhosis in chronic hepatitis B patients. J Med Plants. 2005;4(Suppl 1):1-6.
2. Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology (Carlton). 2003;8:256-60.
3. Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol. 2008;28:628-40.
4. Sekkat S, Kamal N, Benali B, et al. [Prevalence of anti-HCV antibodies and seroconversion incidence in five haemodialysis units in Morocco]. Nephrol Ther. 2008;4:105-10. French.
5. Khattab OS. Prevalence and risk factors for hepatitis C virus infection in hemodialysis patients in an Iraqi renal transplant center. Saudi J Kidney Dis Transpl. 2008;19:110-5.
6. Mello Lde A, de Melo-Junior MR, de Albuquerque AC, Coelho MR. [Hepatitis C serum prevalence in hemodialyzed patients]. Rev Soc Bras Med Trop. 2007;40:290-4. Portuguese.
7. Ocak S, Duran N, Kaya H, Emir I. Seroprevalence of hepatitis C in patients with type 2 diabetes mellitus and non-diabetic on haemodialysis. Int J Clin Pract. 2006;60:670-4.
8. Amiri ZM, Shakib AJ, Toorchi M. Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran. East Mediterr Health J. 2005;11:372-6.
9. Albuquerque AC, Coelho MR, Lopes EP, Lemos MF, Moreira RC. Prevalence and risk factors of hepatitis C virus infection in hemodialysis patients from one center in Recife, Brazil. Mem Inst Oswaldo Cruz. 2005;100:467-70.
10. Medeiros MT, Lima JM, Lima JW, Campos Hde H, Medeiros MM, Coelho Filho JM. [Prevalence and associated factors to hepatitis C in hemodialysis patients in Brazil]. Rev Saude Publica. 2004;38:187-93. Portuguese.
11. Espinosa M, Martn-Malo A, Ojeda R, et al. Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences. Am J Kidney Dis. 2004;43:685-9.
12. Jabbari A, Besharat S, Khodabakhshi B, Gorgan I. Hepatitis C in Hemodialysis Centers of Golestan Province, Northeast of Iran (2005). Hepat Mon. 2007;8:61-5.
13. Saxena AK, Panhotra BR, Sundaram DS, et al. Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unit of the middle east. Am J Infect Control. 2003;31:26-33.
14. Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65:2335-42.
15. Gallego E, Lopez A, Perez J, et al. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract. 2006;104:c1-6.
16. Kalia H, Lopez PM, Martin P. Treatment of HCV in patients with renal failure. Arch Med Res. 2007;38:628-33.
17. Saxena AK, Panhotra BR. The impact of nurse understaffing on the transmission of hepatitis C virus in a hospital-based hemodialysis unit. Med Princ Pract. 2004;13:129-35.
18. Petrosillo N, Gilli P, Serraino D, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis. 2001;37:1004-10.
19. Alfurayh O, Sabeel A, Al Ahdal MN, et al. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol. 2000;20:103-6.
20. Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S. Hepatitis B and C in dialysis units in Iran: Changing the epidemiology. Hemodial Int. 2008;12: 378-82.
21. Alavian SM, Bakhtiari S, Hajariazdeh B. Transfusion remains a risk factor for hepatitis C acquisition among patients on hemodialysis. Transfusion Today. 2002;50:4-5.
22. Alavian SM, Hajarizadeh B. Remarkable difference in the mode of HCV transmission among haemodialysis patients and IVDAs. Gut. 2004;53:1057.
23. Alavian SMM. Hepatitis C, Chronic Renal Failure, Control Is Possible! Hepat Mon. 2006;6:51-552.
24. Nemati E, Taheri S, Einollahi B, Sir D. Hepatitis C among Hemodialysis Patients: Impact of Strict Adherence to Universal Precautions. Hepat Mon. 2007;7:245-6.
25. Dattolo P, Lombardi M, Ferro G, Michelassi S, Cerrai T, Pizzarelli F. [Natural history of HCV infection and risk of death in a cohort of patients on long-term hemodialysis]. G Ital Nefrol. 2006;23:585-90. Italian.
26. Martin P, Fabrizi F. Treatment of chronic hepatitis C infection in patients with renal failure. Clin Gastroenterol Hepatol. 2005;3:S113-7.
27. Marcelli D, Stannard D, Conte F, Held PJ, Locatelli F, Port FK. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int. 1996;50:1013-8.
28. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis. 1998;32:629-34.
29. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 2000;11: 1896-902.
30. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Metaanalysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20:1271-7.
31. Okuda K, Yokosuka O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4-23 years of follow-up. World J Gastroenterol. 2004;10:2209-12.
32. Alavian SM, Hosseini-Moghaddam SM, Rahnavardi M. Hepatitis C among Hemodialysis Patients: A Review on Epidemiologic, Diagnostic, and Therapeutic Features. Hepat Mon. 2007;7:153-62.
33. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. 1st ed. London: John Wiley & Sons Ltd; 2009.
34. Petitti DB. Meta-Analysis, decision analysis, and costeffectiveness analysis: methods for quantitative synthesis in medicine. 2nd ed. New York: Oxford University Press; 2000.
35. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
36. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101.
37. Egger M, Davey Smith G, Schneider M, Ce M. Bias in meta-analysis detected by a simple graphical test. BMJ. 1997;315:629-34.
38. Chan TM, Ho SK, Tang CS, et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology (Carlton). 2007;12:11-7.
39. Amarapurkar DN, Patel ND, Kirpalani AL. Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis. Trop Gastroenterol. 2007 Jan;28:16-8.
40. Uchihara M, Izumi N, Sakai Y, et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron. 1998;80:51-6.
41. Artan R, Akcam M, Yilmaz A, Kocacik D. Interferon alpha monotherapy for chronic hepatitis C viral infection in thalassemics and hemodialysis patients. J Chemother. 2005;17:651-5.
42. Grgurevic I, Vince A, Buljevac M, et al. Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared. Nephron Clin Pract. 2006;103:c8-11.
43. Chow WC, Tien SL, Tan CK, Lui HF, Vathsala A, Ng HS. Treatment of chronic hepatitis C in patients with end-stage renal disease and hemophilia--the Singapore experience. Intervirology. 2006;49:107-11.
44. Djordjevic V, Kostic S, Stefanovic V. Treatment of chronic hepatitis C with interferon alpha in patients on maintenance hemodialysis. Nephron. 1998;79:229-31.
45. Potthoff A, Wiegand J, Luth JB, Wedemeyer H, Manns MP, Tillmann HL. Superiority of standard interferonalpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin Nephrol. 2005;63:232-5.
46. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2006;21:437-43.
47. Urbanek P, Tesar V, Prochazkova-Francisci E, Lachmanova J, Marecek Z, Svobodnik A. Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-alpha. Treatment of hepatitis C. Blood Purif. 2004;22:344-50.
48. Gursoy M, Gur G, Arslan H, Ozdemir N, Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat. 2001;8:70-7.
49. Pol S, Thiers V, Carnot F, Zins B, Romeo R, Berthelot P, et al. Effectiveness and tolerance of interferon-alpha 2b in the treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant. 1996;11 Suppl 4:58-61.
50. Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol. 2007;46:768-74.
51. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc. 2004;36:1831-4.
52. Mousa D, Alsulaiman M, Alhawas F, Alharbi W. The combination therapy of ribavirin and pegylated interferon in non-responder, chronic HCV infection, hemodialysis patients. Nephrol Dial Transplant. 2007;22:197.
53. Deltenre V, Canva F, Provot F. Pegylated interferon and ribavirin in haemodialyzed patients with chronic hepatitis C: A prospective study. Hepatology. 2006;44:S329A.
54. Izumi N AY, Kurosaki M, Uchihara M, et al. A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load. Intervirology. 2004;47:102-7.
55. Tuglular SKH, Karakullukcu F, Erman M, et al. Preliminary results of interferon compared to interferon combined with ribavirin in the treatment of chronic HCV in patients on chronic hemodialysis [abtract]. J Am Soc Nephrol. 2001;:12.
56. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat. 2006;13: 316-21.
57. van Leusen R, Adang RP, de Vries RA, et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant. 2008;23:721-5.
58. Arambarri M, Fernandez Lucas M, Echarri R, et al. Therapy with interferon plus ribavirin in hemodialysis patient with PCR-positive viral hepatitis C. Nefrologia. 2004;24 Suppl 3:39-42.
59. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - A pilot study. J Viral Hepat. 2001;8:287-92.
60. El-Zayadi AR, Barakat EM, Badran HM, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of Peginterferon-alpha2b/ribavirin or induction-dose interferonalpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol. 2005;100:2447-52.
61. Fernandez I, Meneu JC, Colina F, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl. 2006;12:1805-12.
62. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin in haemodialysis patients. Nephrol Dial Transplant. 2006;21:1444-5.
63. Tan AC, Adang R, Konings S, Cnossen N, Schalm SW, van Leusen R. Treatment with peg-interferon and ribavirin therapy in dialysis patients with chronic hepatitis C. Hepatology. 2006;44:321A.
64. Ellis ME, Halim MA, Sieck JO, et al. Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha. J Hepatol. 1993;18:210-6.
65. Benci A, Caremani M, Menchetti D, Sasdelli M, Giusti PB. Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C. Curr Med Res Opin. 1998;14:141-4.
66. Kamar N, Toupance O, Buchler M, et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol. 2003;14:2092-8.
67. Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol. 2001;21:435-40.
68. Mahmoud IH, Elhabashi AF, Sally ST, Elsawy E, Bayoumy A, Ghoneim M. Interferon therapy in hemodialysis patients with type C chronic hepatitis: tolerance, efficacy, and posttransplant course. Nephrol Dial Transplant. 2002;17:110.
69. Lutz Renders PW, Hauser I. Efficacy, side effects and follow up after renal transplantation of a high dose interferon alpha 2a therapy in hemodialysis patients. Nephrol Dial Transplant. 2002;17:111.
70. Tokumoto T, Tanabe K, Ishikawa N, et al. Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc. 1999;31:2887-9.
71. Taltavull TC, Baliellas C, Benasco C, et al. Efficacy of interferon (IF) in chronic HCV hepatitis in kidney transplant (KT) candidates on hemodialysis (HD). Results after KT. Hepatology. 1996;24:598.
72. Casanovas-Taltavull T, Baliellas C, Benasco C, et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol. 2001;96:1170-7.
73. Kose S, Gurkan A, Akman F, Kelesoglu M, Uner U. Treatment of hepatitis C in hemodialysis patients using pegylated interferon alpha-2a in Turkey. J Gastroenterol. 2009;44:353-8.
74. Sporea I, Sirli R, Golea O, Totolici C, Danila M, Popescu A. Peg-Interferon Alfa 2a (40kDa) in patients on chronic haemodialysis with chronic C hepatitis. Preliminary results. Rom J Gastroenterol. 2004;13:99-102.
75. Ucmak H, Kokoglu OF, Hosoglu S, et al. Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients. Ren Fail. 2008;30:227-32.
76. Fernandez JL, Rendo P, Del Pino N, Viola L, Cusumano A. A controlled trial of interferon alfa 2b in hemodialysis patients with chronic hepatitis C. J Am Soc Nephrol. 1996;7:1446.
77. Maftei ID, Ionita-Radu F, Totolici C, et al. Safety and efficacy analysis of pegylated-interferon alpha-2a therapy in hepatitis C virus positive haemodialysis (HCV-HD) patients: Results from a large, multicentric audit. Nephrol Dial Transplant. 2006;21:556.
78. Russo MW, Sigal SH, Joshi V, Detwiler R, Andreoni, K, Shrestha R. A multi-center randomized trial of pegylated interferon alfa-2B monotherapy (PEG-INTRON) in patients with chronic hepatitis C and end stage kidney disease on dialysis. Hepatology. 2004;40:399A.
79. Alfurayh O, Pall A, Ellis M, Chaudry T, Almeshari K. Randomised controlled trial of interferon-a (ifna) in patients with chronic hepatitis C (hcv) on haemodialysis (hd) [abstract]. Nephrol Dial Transplant. 2000;:A106.
80. Alfurayh O, Pall A, Al Mutawa N, et al. Long-term follow up of haemodialysis (hd) patients with chronic hepatitis C (hcv) infection - favorable outcome with a-interferon (ifn) followed by kidney transplantation. Nephrol Dial Transplant. 2002;:110-1.
81. Ozdemir FN, Akcay A, Sezer S, et al. A six-year follow-up after interferon-alpha monotherapy for chronic hepatitis C infection in hemodialysis patients. Ren Fail. 2004;26: 583-8.
82. Rocha CM, Perez RM, Ferreira AP, et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int. 2006;26:305-10.
83. Rocha CM, Perez RM, Narciso JL, et al. Interferonalpha therapy within the first year after acute hepatitis C infection in hernodialysis patients: efficacy and tolerance. Eur J Gastroenterol Hepatol. 2007;19:119-23.
84. Raptopoulou-Gigi M, Spaia S, Garifallos A, et al. Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant. 1995;10:1834-7.
85. Chan TM, Wu PC, Lau JY, Lok AS, Lai CL, Cheng IK. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant. 1997;12:1414-9.
86. Fernandez JL, Rendo P, del Pino N, Viola L. A doubleblind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. J Viral Hepat. 1997;4:113-9.
87. Izopet J, Rostaing L, Moussion F, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis. 1997;176:1614-7.
88. Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant. 1999;14:2704-9.
89. Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant. 2001;16:1017-23.
90. Hanrotel C, Toupance O, Lavaud S, et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron. 2001;88:120-6.
91. Mahmoud IM, Sobh MA, El-Habashi AF, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract. 2005;100:c133-9.
92. Liu CH, Liang CC, Lin JW, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut. 2008;57:525-30.
93. Huraib S, Tanimu D, Romeh SA, et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis. 1999;34:55-60.
94. Rostaing L, Izopet J, Moussion F, et al. [HCV RNA clearance after treatment with interferon-alpha in chronic hemodialysis patients with or without coinfection by HGV/ HGBV-C]. Nephrologie. 1997;18:281-6. French.
95. Pol S, Thiers V, Carnot F, et al. Effectiveness and tolerance of interferon-?2b in the treatment of chronic hepatitis C in haemodialyis patients. Nephrol Dial Transplant. 1996;11:58-61.
96. Buargub M, El Huni S, Tagdi M. Tolerance and efficacy of interferon-alpha in hemodialysis patients in Tripoli. Saudi J Kidney Dis Transplant. 2006;17:338-43.
97. Espinosa M, Rodriguez M, Martin-Malo A, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol. 2001;55:220-6.
98. Huang CCC, Chian CYF. Interferon alpha therapy for hemodiaiysis patients with chronic hepatitis. J Am Soc Nephrol. 1996;7:1449.
99. Zoppoli G, Di Maio G, Artioli S, et al. Monotherapy with pegylated interferon alpha-2a in hemodialyzed patients with chronic hepatitis C. Dialysis Transplant. 2008;37: 204-8.
100. Akhan SC, Kalender B, Ruzgar M. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection. Infection. 2008;36:341-4.
101. Ayaz C, Celen MK, Yuce UN, Geyik MF. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World J Gastroenterol. 2008;14:255-9.
102. Sikole A, Dzekova P, Selja N, et al. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy. Ren Fail. 2007;29:961-6.
103. Casanovas-Taltavull T, Baliellas C, Llobet M, et al. Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant Proc. 2007;39:2125-7.
104. Espinosa M, Arenas MD, Aumente MD, et al. Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients. Clin Nephrol. 2007;67:366-73.
105. Kokoglu OF, Ucmak H, Hosoglu S, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol. 2006;21:575-80.
106. Covic A, Maftei ID, Mardare NG, et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol. 2006;19:794-801.
107. Dzekova P, Asani A, Selim G, et al. Long-term follow up of sustained viral response after treatment of hepatitis C with pegylated interferon a-2a in hemodialysis patients. Int J Artif Organs. 2009;32:180-4.
108. Tan SS, Abu Hassan MR, Abdullah A, Ooi BP, Korompis T, Merican MI. Safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2b in the treatment of haemodialysis patients with chronic hepatitis C. J Viral Hepat. [In press 2009].
109. Okuda K, Hayashi H, Yokozeki K, Kondo T, Kashima T, Irie Y. Interferon treatment for chronic hepatitis C in haemodialysis patients: suggestions based on a small series. J Gastroenterol Hepatol. 1995;10:616-20.
110. Sporea I, Golea O, Ursu C, et al. Effect of alpha 2b interferon treatment in hemodialyzed patients with chronic hepatitis C. Romanian J Gastroenterol. 2001;10:285-8.
111. Sauk J, Jensen DM, Mohanty SR, Reau N, Reddy KG, Te HS. Lack of efficacy of pegylated interferon monotherapy for hepatitis C in patients with end-stage renal disease on dialysis. Gastroenterol Hepatol. 2006;2:504-8.
112. Sporea I, Popescu A, Sirli R, et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol. 2006;12:4191-4.
113. Koenig P, Vogel W, Umlauft F, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int. 1994;45:1507-9.
114. Rivera M, Gentil MA, Sayago M, et al. Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant. Transplant Proc. 2005;37:1424-5.
115. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis. 2008;51:263-77.
116. Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J Viral Hepat. 2008;15: 79-88.
117. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Metaanalysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther. 2003;18(11-12):1071-81.
118. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon for hepatitis C virus in hemodialysis-an individual patient meta-analysis of factors associated with sustained virological response. Clin J Am Soc Nephrol. 2009;4:1449-58.